2023年AD治疗药物行业热点追踪：度普利尤之后，新一代AD治疗生物制剂前瞻

2023-11-21 14:11:21上传人：遗忘**en
Aa 小中大

分享到：

投资要点：电子板块观点：2023Q3中国大陆高端智能手机出货量同比增长12.3%，双十一购物季期间小米和华为手机出货量均实现超40%同比增长，国内智能手机市场有望步入复苏轨道；联想2023/2024第二财季业绩环比改善，随着去库存周期接近尾声，PC市场有望重启增长。整体产业处于逐步回暖阶段，建议关注周期筑底、国产替代、汽车

CONTENTS
©2023 LeadLeo www.leadleo.com400
072 -5588
 Terms --------------------------------------------------------------------- 05
 Evolution of Treatment Modalities for AD --------------------------------------------------------------------- 06
• Demand for AD Treatment in China --------------------------------------------------------------------- 07
•The Evolution of AD Treatment Modalities --------------------------------------------------------------------- 08
 Current Status of Biological Agents for the Treatment of AD --------------------------------------------------------------------- 09
•Mechanisms of Biological Agents in the Treatment of AD --------------------------------------------------------------------- 10
•Competitive Landscape of IL -4Rα Target Biologics In China --------------------------------------------------------------------- 11
•Introduction to Dupixent --------------------------------------------------------------------- 12
•The Characteristics of AD Indicate the Future Direction of Biologics --------------------------------------------------------------------- 13
 The Development Direction of Next -generation AD Biologics --------------------------------------------------------------------- 14
•Longer Interval between Dosing Frequencies --------------------------------------------------------------------- 15
•More Effective and Have a Faster Onset of Action in the First 16 Weeks --------------------------------------------------------------------- 16
•Efficacy Continues to Improve and the Maintenance Period is Long
lasting after 16 weeks --------------------------------------------------------------------- 17
•
Better Security --------------------------------------------------------------------- 18
 Methodology --------------------------------------------------------------------- 19
 Legal Statement --------------------------------------------------------------------- 20
目录
CONTENTS